Furthermore, data from cBioPortal and Vizome databases showed that no mutation of TESPA1 was present in patients with AML and no more than 0.1% mutations of TESPA1 in patients with other types of leukemia [57, 58], suggesting that TESPA1 may be a relatively stable target for clinical treatment of AML. Here, TESPA1 is linked to acute myeloid leukemia.